Figure 3.
Human intravenous immunoglobulin (hIVIG) reduces enterovirus D68 (EV-D68)–induced motor impairment and viral loads. A, Motor impairment scores for mice infected by intramuscular inoculation with 103 EV-D68 IL/14-18952 and then given hIVIG by intraperitoneal injection at either 1 day (n = 8), 3 days (n = 11), 4 days (n = 11), or 6 days (n = 12) after infection. Control mice received an intraperitoneal injection of phosphate-buffered saline (n = 40). Data for animals surviving to the end of the study were graphed. B and C, Mice were treated with hIVIG (n = 10) or control (n = 7) on day 3 after infection. On day 6 after infection, muscle (open squares) and spinal cord (filled circles) tissue specimens were collected for viral titer analysis. Error bars are standard errors of the mean. *P ≤ .05 , **P ≤ .01, and ****P ≤ .0001.